Ergoloid mesylates are avoided in older adults mainly due to:

• A. Strong efficacy for cognitive enhancement.
• B. Lack of efficacy.
• C. They are essential for delirium prevention.
• D. They improve sleep quality.

Answer: (B)

In older adults, the risk–benefit balance is crucial: a medication should show proven benefit to justify its use given the potential for harm in this population. Ergoloid mesylates have been used for cognitive issues, but high-quality evidence does not show meaningful cognitive improvement or delirium-prevention benefits. Without proven benefit, continuing the drug exposes older patients to adverse effects such as dizziness, orthostatic hypotension, GI upset, and tachycardia, without a corresponding improvement in outcomes. That is why they are avoided. The other options imply benefits that aren’t supported by evidence—there isn’t strong efficacy, essential delirium prevention, or sleep quality improvement to justify use.